Uno studio di fase IIB, randomizzato, in doppio cieco, controllato con placebo di ElismEtrep (K-304) nel trattamento dell'emicrania
Uno studio di fase IIB, randomizzato, in doppio cieco, controllato con placebo di ElismeTrep (K-304) nel trattamento dell'emicrania: verrà valutata una gamma di dosi
This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep as compared to placebo in the acute treatment of migraine.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
Alabama
-
Birmingham, Alabama, Stati Uniti, 35205
- Central Research Associates, LLC (CRA) dba Flourish Research
-
Mobile, Alabama, Stati Uniti, 36608
- AMR Mobile
-
-
Arizona
-
Tucson, Arizona, Stati Uniti, 85710
- Wake Research/ Tucson Neuroscience Research
-
-
California
-
Canoga Park, California, Stati Uniti, 91303
- Hope Clinical Research
-
Encino, California, Stati Uniti, 91316
- WR-PRI, LLC (Encino)
-
Huntington Beach, California, Stati Uniti, 92647
- Marvel Clinical Research
-
La Mesa, California, Stati Uniti, 91942
- Eximia Research - CA
-
Lemon Grove, California, Stati Uniti, 91945
- Synergy San Diego
-
Newport Beach, California, Stati Uniti, 92660
- WR-PRI, LLC (Newport Beach)
-
Oceanside, California, Stati Uniti, 92056
- Excell Research, Inc.
-
Pomona, California, Stati Uniti, 91767
- Empire Clinical Research
-
Riverside, California, Stati Uniti, 92503
- Artemis Institute for Clinical Research - Riverside
-
San Diego, California, Stati Uniti, 89109
- Acclaim Clinical Research
-
San Diego, California, Stati Uniti, 92103
- Artemis Institute for Clinical Research - San Diego
-
Walnut Creek, California, Stati Uniti, 94598
- Diablo Clinical Research, Inc.
-
West Hills, California, Stati Uniti, 91307
- Focus Clinical Research
-
-
Connecticut
-
Cromwell, Connecticut, Stati Uniti, 06416
- CT Clinical Research
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30329
- DelRicht Research
-
Stockbridge, Georgia, Stati Uniti, 30281
- Clinical Research Atlanta - Stockbridge
-
-
Idaho
-
Boise, Idaho, Stati Uniti, 83704
- Northwest Clinical Trials
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60607
- Cedar Crosse Research Center
-
Flossmoor, Illinois, Stati Uniti, 60422
- Healthcare Research Network II, LLC
-
-
Kansas
-
Overland Park, Kansas, Stati Uniti, 66202
- Collective Medical Research
-
Wichita, Kansas, Stati Uniti, 67207
- Alliance for Multispecialty Research
-
-
Kentucky
-
Louisville, Kentucky, Stati Uniti, 40213
- L-MARC Research Center
-
-
Louisiana
-
Chalmette, Louisiana, Stati Uniti, 70043
- Crescent City Headache & Neurology Center
-
New Orleans, Louisiana, Stati Uniti, 70115
- DelRicht Research
-
-
Michigan
-
Ann Arbor, Michigan, Stati Uniti, 48104
- Michigan Head Pain and Neurological Institute
-
-
Minnesota
-
Minneapolis, Minnesota, Stati Uniti, 55402
- Clinical Research Institute
-
-
Mississippi
-
Gulfport, Mississippi, Stati Uniti, 39503
- DelRicht Research
-
-
Missouri
-
Hazelwood, Missouri, Stati Uniti, 63042
- Healthcare Research Network
-
-
Nevada
-
Las Vegas, Nevada, Stati Uniti, 89109
- Excel Clinical Research
-
North Las Vegas, Nevada, Stati Uniti, 89119
- Las Vegas Clinical Trials
-
-
New Mexico
-
Albuquerque, New Mexico, Stati Uniti, 87102
- Albuquerque Clinical Trials, Inc.
-
-
New York
-
Amherst, New York, Stati Uniti, 14226
- Dent Neurosciences Research Center
-
Manlius, New York, Stati Uniti, 13104
- CNY Clinical Research
-
Rochester, New York, Stati Uniti, 14609
- Rochester Clinical Research
-
Williamsville, New York, Stati Uniti, 14221
- Upstate Clinical Research Associates LLC
-
-
North Carolina
-
Greensboro, North Carolina, Stati Uniti, 27405
- Headache Wellness Center
-
High Point, North Carolina, Stati Uniti, 27260
- Peters Medical Research
-
-
Ohio
-
Cincinnati, Ohio, Stati Uniti, 45212
- CTI Clinical Research Center
-
-
Oklahoma
-
Edmond, Oklahoma, Stati Uniti, 73034
- OK Clinical Research, LLC
-
Oklahoma City, Oklahoma, Stati Uniti, 73102
- Hightower Clinical
-
Tulsa, Oklahoma, Stati Uniti, 74133
- DelRicht Research
-
Yukon, Oklahoma, Stati Uniti, 73099
- Tekton Research
-
-
Oregon
-
Portland, Oregon, Stati Uniti, 97210
- Summit Research Network
-
-
Pennsylvania
-
Allentown, Pennsylvania, Stati Uniti, 18103
- Lehigh Center for Clinical Research
-
Philadelphia, Pennsylvania, Stati Uniti, 19114
- Clinical Research Philadelphia, LLC
-
Scottdale, Pennsylvania, Stati Uniti, 15683
- Frontier Clinical Research, LLC
-
Smithfield, Pennsylvania, Stati Uniti, 15478
- Frontier Clinical Research, LLC
-
West Chester, Pennsylvania, Stati Uniti, 19380
- Atlas-Clinical
-
-
South Carolina
-
Charleston, South Carolina, Stati Uniti, 29406
- Clinical Trials of South Carolina
-
North Charleston, South Carolina, Stati Uniti, 29405
- Coastal Carolina Research Center
-
-
Tennessee
-
Chattanooga, Tennessee, Stati Uniti, 37421
- WR-ClinSearch
-
Knoxville, Tennessee, Stati Uniti, 37909
- AMR Knoxville (Formerly NOCCR)
-
Nashville, Tennessee, Stati Uniti, 37203
- Clinical Research Associates, Inc.
-
-
Texas
-
Austin, Texas, Stati Uniti, 78745
- Tekton Research
-
Austin, Texas, Stati Uniti, 78737
- Donald J Garcia Jr, MD, PA
-
Dallas, Texas, Stati Uniti, 75251
- FutureSearch Trials of Dallas, LP
-
Houston, Texas, Stati Uniti, 77024
- Victorium Clinical Research LTD CO
-
Splendora, Texas, Stati Uniti, 77372
- APD Clinical Research
-
Waxahachie, Texas, Stati Uniti, 75165
- ClinPoint Trials
-
-
Utah
-
Ogden, Utah, Stati Uniti, 84405
- Advanced Research Institute
-
-
Virginia
-
Newport News, Virginia, Stati Uniti, 23606
- Health Research of Hampton Roads, Inc.
-
-
West Virginia
-
Morgantown, West Virginia, Stati Uniti, 26505
- Frontier Clinical Research, LLC
-
-
Wisconsin
-
Kenosha, Wisconsin, Stati Uniti, 53144
- Clinical Investigation Specialist
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Be a male or female, age 18 to 70 years, inclusive, at the time of signing informed consent.
-
Participant has greater than a one-year history of migraine with or without aura as defined by International Conference on Harmonization (IHS) criteria 1.1 and 1.2 and his/her migraines typically last between 4 to 72 hours, if untreated as documented in the participant's medical records from his/her treating physician and confirmed by the investigator.
-
Participant has had ≥2 and ≤10 moderate or severe migraine attacks per month in each of the two months prior to screening (Visit 1).
-
Meet the following requirements:
-
Is a male OR
-
Is a female who is of non-childbearing potential defined by at least 1 of the following criteria:
-
Postmenopausal (aged >45 years and with a minimum of 12 months of spontaneous amenorrhea with a screening serum follicle-stimulating hormone (FSH) level in the menopausal range established for the central laboratory.
-
Post hysterectomy, bilateral oophorectomy or bilateral salpingectomy, based on the participant's recall of their medical history.
OR
-
Is a female of reproductive potential and:
-
agrees to remain abstinent from heterosexual activity*
*Abstinence can be used as the sole method of contraception if it is in line with the participant's preferred and usual lifestyle and if considered acceptable by local regulatory agencies and ethics committees. Periodic abstinence (e.g., calendar, ovulation, sympto-thermal, post-ovulation methods, etc.) and withdrawal are not acceptable methods of contraception.
-
or agrees to use (or have their partner use) a birth control method that is acceptable from the first dose of study drug until the end of trial (EoT) visit. Acceptable methods of birth control are:
-
combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation:
- oral
- intravaginal
- transdermal
-
progestogen-only hormonal contraception associated with inhibition of ovulation:
- oral
- injectable
- implantable
-
intrauterine device (IUD)
-
intrauterine hormone-releasing system (IUS)
-
bilateral tubal occlusion
-
vasectomised partner
-
sexual abstinence
-
progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action
-
male or female condom with or without spermicide
-
cap, diaphragm or sponge with spermicide
-
A combination of male condom with either cap, diaphragm or sponge with spermicide (double barrier methods)
-
This condition is waived if the participant is proven to have no child-bearing potential (eg, hysterectomy).
-
-
Participant voluntarily agrees to participate in the study by giving written informed consent.
-
Participant is able to read, understand and complete the study questionnaires and diary.
-
Be willing and able to comply with the study schedule of visits, all trial procedures and restrictions.
-
Be willing to use their own personal, qualified smartphone to download study specific eDiary applications for use during the study.
Exclusion Criteria:
-
Is a female who is pregnant, breast-feeding or intends to become pregnant during the planned course of the study. Note: Participants must have a negative serum pregnancy test (β-human chorionic gonadotropin (β-hCG)) performed by the central laboratory prior to enrollment in the study and negative urine pregnancy result at the randomization visit.
Migraine history related
-
Participant has difficulty distinguishing his/her migraine attacks from tension-type headaches.
-
Participant has a history of predominantly mild migraine attacks or migraines that usually resolve spontaneously in less than two hours.
-
Participant has more than 15 headache-days per month or has taken medication for acute headache on more than 10 days per month in any of the three months prior to screening (Visit 1).
-
Participant has brainstem (a.k.a. basilar-type) or hemiplegic migraine headache, or retinal migraine.
-
Participant was >50 years old at age of first migraine onset.
-
Participant is taking migraine prophylactic medication where the prescribed daily dose has changed during the 3 months prior to screening (Visit 1) or anticipates any change during the study. Any withdrawal of preventive medications for the treatment of migraine should be completed at least 30 days prior to screening.
Medical history related
-
Participant has, in the opinion of the investigator, other confounding pain syndromes, psychiatric conditions such as uncontrolled major depression, history of psychosis, dementia or significant neurological disorders other than migraine [participants who are currently being treated with non-prohibited medication for depression and symptoms are well controlled, in the opinion of the investigator, are eligible to participate in this study].
-
Participant is at imminent risk of self-harm, based on clinical interview and responses on the Columbia Suicidality Severity Rating Scale (C-SSRS), or of harm to others in the opinion of the investigator. Participants must be excluded if they report suicidal ideation with intent, with or without a plan (i.e., Type 4 or 5 on the C-SSRS) in the past 2 months or suicidal behavior in the past 6 months.
-
Has a recent history (within the past 3 years of the Screening Visit) or current diagnosis or evidence of endocrine, hematological, immunological, renal, respiratory, neurologic, gastrointestinal, biliary, or genitourinary abnormalities or diseases that, per the investigator's judgement, may jeopardize the participant's safety or compliance with the protocol, or otherwise interfere with interpretation of efficacy and/or safety results.
-
Has a history of malignant neoplasms within the past 5 years prior to screening. Basal and squamous cell skin cancer and any carcinoma in-situ are allowed if they have received treatment and follow-up consistent with local standard of care.
-
Participant history with current evidence of uncontrolled, unstable or recently diagnosed cardiovascular disease, such as ischemic heart disease, coronary artery vasospasm, and cerebral ischemia. Participants with Myocardial Infarction (MI), Acute Coronary Syndrome (ACS), percutaneous Coronary Intervention (PCI), cardiac surgery, stroke or transient ischemic attack (TIA) during the 6 months prior to screening.
-
Has a history of human immunodeficiency virus disease.
-
Participant has a history of gastric or small intestinal surgery (including gastric bypass surgery or banding but not including cholecystectomy or appendectomy) or has a disease that causes malabsorption.
Laboratory, vital sign, and electrocardiogram (ECG) related
-
Has a positive test result at screening for hepatitis B surface antigen (Ag), hepatitis C virus antibody.
-
Has a screening estimated Glomerular Filtration Rate (eGFR) estimated with the Modification of Diet in Renal Disease (MDRD) equation of <45 ml/min/1.73 m^2.
-
Has a screening result for alanine aminotransferase or aspartate aminotransferase (ALT or AST) of >2.0X upper limit of normal (ULN) or total bilirubin >1.5X ULN at the Screening Visit. Note: An isolated bilirubin >1.5X ULN is acceptable if bilirubin is fractionated, and direct bilirubin is within the laboratory normal range.
-
Has a corrected QT interval to Fridericia's formula (QTcF) >450 milliseconds (msec) for males and >470 msec for females at screening.
-
Has a mean value for triplicate seated systolic blood pressure >160 mmHg and/or diastolic blood pressure (BP) >95 mmHg measured after at least 5 minutes at rest at the Screening Visit.
Note: If a participant's BP is exclusionary on the first triplicate assessment at the Screening Visit, they may have 1 repeat triplicate BP assessment at that visit after another rest of at least 10 minutes.
Medication use and substance abuse related
-
Has known history of or suspected abuse of alcohol or recreational drugs at screening.
-
Has use of soft drugs (such as marijuana or any substances containing tetrahydrocannabinol (THC) or cannabidiol (CBD)) within 3 months prior to screening, or hard drugs (such as cocaine, illicit narcotics/opiates) within 6 months prior to screening.
-
Has a positive drug screen at screening. Note: If benzodiazepines are detected on the drug screen, this is not exclusionary if they are prescribed a benzodiazepine for a therapeutic purpose (e.g. for insomnia) and confirmatory documentation is obtained from the prescribing physician.
-
Is currently in violation of study requirements for prohibited and permissible concomitant medications (not already specified in other criteria) or is anticipated to violate these requirements during study participation.
-
Has any use of prescription opiate medications within 14 days of screening or any anticipated/potential use of opiates during study participation.
-
History of use of ergotamine medications on greater than/equal 10 days per month on a regular basis for greater than/equal 3 months prior to screening.
-
History of non-narcotic analgesic intake on greater than/equal 15 days per month for greater than/equal 3 months prior to screening.
Other
-
Has known or suspected hypersensitivity to trial product(s) or related products.
-
Has a history of multiple significant and/or any severe allergies (e.g., food, drug, latex allergy) or has had an anaphylactic reaction or significant intolerance to prescription or nonprescription drugs or food.
-
Has any surgery scheduled for the duration of the trial.
-
Had major surgery or donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the Screening Visit; has a screening hemoglobin <11.0 g/dL (males) or <10.0 g/dL (females), or has a known hemoglobinopathy (e.g. sickle cell anemia, hemolytic anemia).
-
Has previous participation in this trial. Participation is defined as signed informed consent.
-
Has participated in any clinical trial of an approved or non-approved investigational biological medicinal product (e.g. antibody therapy) within 90 days of screening or has participated in any clinical trial of an approved or non-approved investigational small molecule medicinal product within 30 days or 5 half-lives (whichever is longer) of screening.
-
Has any other disorder, unwillingness or inability, not covered by any of the other exclusion criteria, which in the investigator's opinion, might jeopardize the participant's safety or compliance with the protocol, or otherwise interfere with interpretation of efficacy and/or safety results.
-
Is an employee or immediate family member (e.g., spouse, parent, child, sibling) of the Sponsor or study site.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Triplicare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Elismetrep (K-304) Dose Level 1
Participants received a single dose of elismetrep 2 mg |
Administered orally |
|
Sperimentale: Elismetrep (K-304) Dose Level 2
Participants received a single dose of elismetrep 5 mg |
Administered orally |
|
Sperimentale: Elismetrep (K-304) Dose Level 3
Participants received a single dose of elismetrep 10 mg |
Administered orally |
|
Sperimentale: Elismetrep (K-304) Dose Level 4
Participants received a single dose of elismetrep 20 mg |
Administered orally |
|
Comparatore placebo: Placebo
Participants received a single dose of elismetrep-matched placebo |
Administered orally |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Pain Freedom
Lasso di tempo: 2 hours post-dose
|
Assessed using the number of evaluable participants that reported no pain at 2 hours post-dose. Pain was measured on a 4-point Likert scale (0 = none, 1 = mild, 2 = moderate, 3 = severe) |
2 hours post-dose
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Proportion of Participants Who Experienced 1 or More Treatment-emergent Adverse Events (AEs)
Lasso di tempo: up to 7 days after administration of study therapy
|
up to 7 days after administration of study therapy
|
|
|
Freedom From the Most Bothersome Symptom (MBS) (Nausea, Phonophobia or Photophobia)
Lasso di tempo: 2 hours post-dose
|
Assessed using the number of evaluable participants that reported the absence of their MBS |
2 hours post-dose
|
|
Pain Relief
Lasso di tempo: 2 hours post-dose
|
Assessed using the number of evaluable participants that reported a pain level of moderate or severe (responses of 2 or 3 on the 4-point Likert scale) at baseline and then reported a pain level of none or mild (response of 0 or 1). |
2 hours post-dose
|
|
Freedom From Photophobia
Lasso di tempo: 2 hours post-dose
|
Assessed by tabulating the number of participants that reported the absence of photophobia at 2 hours post-dose in the subset of participants that reported the presence of photophobia at baseline. |
2 hours post-dose
|
|
Freedom From Phonophobia
Lasso di tempo: 2 hours post-dose
|
Assessed by tabulating the number of participants that reported the absence of phonophobia at 2 hours post-dose in the subset of participants that reported the presence of phonophobia at baseline. |
2 hours post-dose
|
|
Freedom From Nausea
Lasso di tempo: 2 hours post-dose
|
Assessed by tabulating the number of participants that reported the absence of nausea at 2 hours post-dose in the subset of participants that reported the presence of nausea at baseline. |
2 hours post-dose
|
|
The Probability of Requiring Rescue Medication
Lasso di tempo: 24 hours post-dose
|
Assessed using the number of participants that took rescue medication within 24 hours after administration of study therapy |
24 hours post-dose
|
|
Sustained Pain Freedom
Lasso di tempo: From 2 to 24 hours
|
Assessed using the number of participants that did not experience any headache pain through the time period of interest |
From 2 to 24 hours
|
|
Sustained Pain Relief
Lasso di tempo: From 2 to 24 hours
|
Assessed using the number of participants that did not experience any moderate or severe headache pain through the time period of interest. |
From 2 to 24 hours
|
|
Sustained Pain Freedom
Lasso di tempo: From 2 to 48 hours
|
Assessed using the number of participants that did not experience any headache pain through the time period of interest. |
From 2 to 48 hours
|
|
Sustained Pain Relief
Lasso di tempo: From 2 to 48 hours
|
Assessed using the number of participants that did not experience any moderate or severe headache pain through the time period of interest. |
From 2 to 48 hours
|
|
Proportion of Participants Who Experienced 1 or More Treatment-emergent Serious Adverse Events (SAEs)
Lasso di tempo: Up to 7 days after administration of study therapy
|
Serious adverse events were assessed in the Safety Analysis Set. |
Up to 7 days after administration of study therapy
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Effettivo)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- K-304 P001
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .